【レポートの概要（一部）】
1. Executive Summary
1.1 Top Stem Cell Technology Companies: Overview of Findings
1.2 Report Contents
1.3 Study Methods – Research and Analysis
1.4 Scope and Format of Report
2. Leading US Stem Cell Technology Companies, 2014
2.1 Aastrom Biosciences
2.1.1 Stem Cell Technology Platform
2.1.2 Aastrom: Stem Cell Pipeline, 2014
2.1.2.1 Ixmyelocel-T: Patient-Specific Therapy Reduces Risk of Rejection
2.1.2.2 Orphan Designation to Accelerate Product Development
2.1.3 Sales and Recent Performance, 2012
2.1.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
2.1.5 Aastrom: Stem Cell Revenue Forecast, 2014-2024
2.2 Advanced Cell Technology (ACT)
2.2.1 Stem Cell Technology Platform
2.2.2 ACT: Stem Cell R&D Pipeline, 2014
2.2.2.1 Human Embryonic Stem Cells: Aiding Tissue Repair
2.2.3 Sales and Recent Performance, 2012
2.2.4 ACT: Stem Cell SWOT Analysis, 2014-2024
2.2.5 ACT: Stem Cell Revenue Forecast, 2014-2024
2.3 Bioheart
2.3.1 Bioheart: Stem Cell Pipeline, 2014
2.3.2 Sales and Recent Performance, 2012
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
2.3.4.1 Increased Activity Abroad Will Help Bioheart Attract Investment
2.4 BrainStorm Cell Therapeutics
2.4.1 Brainstorm Cell Therapeutics: Stem Cell Pipeline, 2014
2.4.2 Brainstorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.4.3 Brainstorm Cell Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.4.3.1 Government Grant Will Provide Much Needed Investment
2.5 California Stem Cell Inc.
2.5.1 California Stem Cell: Stem Cell Pipeline, 2014
2.5.2 California Stem Cell: Stem Cells SWOT Analysis, 2014-2024
2.6 International Stem Cell Corporation (ISCO)
2.6.1 ISCO: Stem Cell Pipeline, 2014
2.6.2 Sales and Recent Performance, 2012
2.6.3 ISCO: Stem Cells SWOT Analysis, 2014-2024
2.6.4 Cosmetic Subsidiary Expands Into Asian Market
2.7 NeoStem
2.7.1 NeoStem: Stem Cell Pipeline, 2014
2.7.1.1 AMR-001: Highly Efficacious Therapy for AMI
2.7.1.2 T-Cell Therapy: Using Autologous Immune Cells as Therapy
2.7.1.3 VSEL Technology: Promoting Cell Migration to Site of Damage
2.7.2 Sales and Recent Performance, 2012
2.7.3 NeoStem: Stem Cell SWOT Analysis, 2014-2024
2.7.4 NeoStem: Stem Cell Revenue Forecast, 2014-2024
2.8 Neuralstem
2.8.1 Stem Cell Technology Platform
2.8.2 Neuralstem: Stem Cell Pipeline, 2014
2.8.2.1 NSI-566: Potential Therapy in Multiple Neurological Disorders
2.8.2.2 NSI-189: Deriving Cells from the Hippocampal Region
2.8.3 Sales and Recent Performance, 2012
2.8.4 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
2.8.5 Neuralstem: Stem Cell Revenue Forecast, 2014-2024
2.9 Medistem
2.9.1 Medistem: Stem Cell Pipeline, 2014
2.9.2 Medistem: Stem Cell SWOT Analysis, 2014-2024
2.9.3 Medistem: Stem Cell Revenue Forecast, 2014-2024
2.9.3.1 Expansion of Clinical Indications Through Acquisition
2.10 Osiris Therapeutics
2.10.1 Osiris Therapeutics: Stem Cell Products
2.10.2 Osiris Therapeutics: Stem Cell Pipeline, 2014
2.10.3 Sales and Recent Performance, 2012
2.10.4 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.10.5 Osiris Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.11 Other US Companies Operating in the Stem Cells Technology Industry, 2014
3. Top European and Israeli Stem Cell Technology Companies, 2014
3.1 Apceth
3.1.1 Apceth: Stem Cell Pipeline, 2014
3.1.1.1 Alecmestencel-T: Options for Autologous and Allogeneic Therapy
3.1.1.2 Agenmestencel-T: Genetically-modified Therapy for Cancer
3.1.2 Apceth: Stem Cell SWOT Analysis, 2014-2024
3.1.3 Apceth: Stem Cell Revenue Forecast, 2014-2024
3.2 Cardio3 BioSciences
3.2.1 Cardio3 BioSciences: Stem Cell Pipeline, 2014
3.2.1.1 C-Cure®: Creating New Muscle Cells
3.2.2 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
3.2.3 Cardio3 BioSciences: Stem Cell Revenue Forecast, 2014-2024
3.3 Cell Cure Neurosciences
3.3.1 Cell Cure Neurosciences: Stem Cell Pipeline, 2014
3.3.2 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
3.4 TiGenix
3.4.1 Stem Cell Technology Platform
3.4.2 TiGenix: Stem Cell Products
3.4.2.1 ChondroCelect: One of Few Marketed Stem Cell Products
3.4.3 TiGenix: Stem Cell Pipeline, 2014
3.4.3.1 Cx601: Promoting Natural Close of Fissure
3.4.3.2 Cx611: Landmark Results of a Cell Therapy in Rheumatoid Arthritis
3.4.3.3 Cx621: Novel, Painless Route of Administration?
3.4.4 Sales and Recent Performance, 2012
3.4.5 TiGenix: Stem Cell SWOT Analysis, 2014-2024
3.4.6 TiGenix: Stem Cell Revenue Forecast, 2014-2024
3.5 Gamida Cell
3.5.1 Stem Cell Technology Platform
3.5.1.1 Copper Chelator-based Technology
3.5.1.2 Nicotinamide (NAM) Platform
3.5.2 Gamida Cell: Stem Cell Pipeline, 2014
3.5.2.1 StemEx: Huge Market Potential in Patient Numbers
3.5.2.2 NiCord: Transplanting Two Units of Umbilical Cord Blood
3.5.3 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
3.5.4 Gamida Cell: Stem Cell Revenue Forecast, 2014-2024
3.6 Pluristem Therapeutics
3.6.1 Stem Cell Technology Platform:
3.6.2 Pluristem Therapeutics: Stem Cell Pipeline, 2014
3.6.2.1 PLX-PAD: Clinical Hold Notification May Delay Approval
3.6.2.2 PLX-RAD: Accelerating Cell Engraftment in Bone Marrow Transplantation
3.6.3 US and Korea Licence Partnerships to Drive Revenue
3.6.4 Sales and Recent Performance, 2013
3.6.5 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
3.6.6 Pluristem Therapeutics: Stem Cell Revenue Forecast, 2014-2024
3.7 ReNeuron
3.7.1 ReNeuron: Stem Cell Technology Platform
3.7.2 ReNeuron: Stem Cell Pipeline, 2014
3.7.2.1 ReN001: Groundbreaking Therapy in Development
3.7.2.2 ReN009: Avoiding Possible Limb Amputation
3.7.2.3 ReN003: Grant and Partnership with Leading US University Will Drive Development
3.7.3 Sales and Recent Performance, 2013
3.7.4 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
3.7.5 ReNeuron: Stem Cell Revenue Forecast, 2014-2024
3.8 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
4. Top Asia-Pacific Stem Cell Technology Companies, 2014
4.1 Anterogen
4.1.1 Anterogen: Stem Cell Products
4.1.1.1 Cupistem®: World’s First MSC Product From Adipose Tissue
4.1.1.2 Queencell®:
4.1.2 Anterogen: Stem Cell Pipeline, 2014
4.1.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
4.2 MEDIPOST
4.2.1 Stem Cell Technology Platform
4.2.2 MEDIPOST: Stem Cell Pipeline, 2014
4.2.2.1 Cartistem: A Top 25 Science Technology
4.2.2.2 Neurostem: Restorative Therapy for Neurological Disease
4.2.2.3 Pneumostem: Treatment for Paediatric Population
4.2.2.4 Promostem: Encouraging Engraftment of Cells Following Transplantation
4.2.3 Sales and Recent Performance, 2014
4.2.4 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
4.2.5 MEDIPOST: Stem Cell Revenue Forecast, 2014-2024
4.2.5.1 Collaboration with an Indian Company Expands Reach in Asia
4.3 Mesoblast
4.3.1 Stem Cell Technology Platform
4.3.2 Mesoblast: Stem Cell Pipeline, 2014
4.3.2.1 Immunology and Inflammatory Diseases
4.3.2.2 Spinal Disease
4.3.2.3 Cardiac and Vascular Disease
4.3.2.4 Oncology
4.3.2.5 Other Indications
4.3.3 Sales and Recent Performance, 2012
4.3.4 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
4.3.5 Mesoblast: Stem Cell Revenue Forecast, 2014-2024
4.4 Pharmicell
4.4.1 Pharmicell: Stem Cell Products
4.4.1.1 Hearticellgram-AMI: World First Cell Therapy for Acute Myocardial Infarction
4.4.2 Pharmicell: Stem Cell Pipeline, 2014
4.4.3 Sales and Recent Performance, 2012
4.4.4 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
4.4.5 Pharmicell: Stem Cell Revenue Forecast, 2014-2024
4.5 Stempeutics Research
4.5.1 Stem Cell Technology Platform
4.5.2 Stempeutics Research: Stem Cell Pipeline, 2014
4.5.2.1 Stempeucel®: Launch in Fast-Growing Asian Markets
4.5.2.2 Stempeucare™: Cosmetic Growth Factor Treatment
4.5.3 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
4.5.4 Stempeutics Research: Stem Cell Revenue Forecast, 2014-2024
4.5.4.1 Cipla Alliance to Drive Revenue as Wider Population Targeted
5. The World Stem Cell Technology Market, 2014-2024
5.1 The World Stem Cell Technology Market, 2012
5.2 The World Stem Cell Technology Market: Revenue Forecast to 2024
5.2.1 What Will Drive The World Stem Cell Technology Market Between 2014 and 2024?
5.2.2 What Factors are Likely to Restrain the World Stem Cell Technology Market Between 2014 and 2024?
5.3 The Stem Cell Technology Market: Revenue Forecast by Therapeutic Application, 2014-2024
5.3.1 How Will Market Shares of Leading Stem Cell Therapeutic Applications Change from 2014-2024?
6. Stem Cell Technologies: Industry Trends, 2014-2024
6.1 Strengths and Weaknesses of The Stem Cell Technologies Market
6.2 Strengths
6.2.1 Stem Cells Are Finally Proving Their Worth
6.3 Weaknesses
6.3.1 Many Difficulties Still to Overcome
6.4 Opportunities and Threats in the Stem Cell Technologies Market
6.4.1 Stem Cells Have Unprecedented Clinical Potential
6.4.2 Regulatory and Commercial Instability Threatens the Field
6.5 STEP Analysis of the Stem Cell Technologies Market, 2014-2024
6.5.1 Social Concerns: A Controversial Technology
6.5.2 Technological Developments: Stem Cell Science Still on the March
6.5.3 Economic Factors: Funding Gaps a Concern
6.5.4 Political Issues: State Attitudes Vital to Research Environment
7. Opinions from Research Interviews
7.1 Dr Robin Smith: Chairman and CEO, NeoStem
7.1.1 The Potential of Stem Cell Therapy
7.1.2 Competition in the Stem Cell Arena
7.1.3 NeoStem’s Products and Technology
7.1.4 Concerns over Stem Cell Therapy
7.1.5 Future Directions for NeoStem and Stem Cell Therapy
7.2 Dr Yael Margolin, President and CEO, Gamida Cell
7.2.1 Stem Cell Therapy and Their Therapeutic Promise
7.2.2 Gamida Cell’s NiCord Product and Umbilical Cord Blood
7.2.3 Partnership with a Leading Pharmaceutical Company
7.2.4 Barriers to Stem Cell Therapy Uptake
8. Conclusions
8.1 The US Leads the Field for Stem Cell Research
8.2 Market Remains Under-Capitalised, in Need of Financing
8.3 Many Barriers Still to Overcome for Companies
8.4 New Entrants to the Market Will Increase Competition
【レポート販売概要】
■ タイトル：主要な幹細胞（ステムセル）技術企業分析（2014-2024）■ 英文：Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024
■ 発行日：2014年3月
■ 調査会社：visiongain
■ 商品コード：Visiongain-4052643
■ 調査対象地域：グローバル
- 2014年戦略提言：スペインの血液凝固検査市場Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.SummaryThis comprehensive report contains 400 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the Spanish coagulation testing market during the next five years. The report explores business and techno …
- 糖尿病網膜症（Diabetic Retinopathy）：グローバル臨床試験レビュー（2014年上半期）Diabetic Retinopathy Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Retinopathy. It includes an overview of the trial numbers and their r …
- Petrofac Limited：石油・ガスバリューチェーン分析レポート2013Petrofac Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Petrofac Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Petrofac Limited”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the com …
- Bengal Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- 2012Bengal Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Bengal Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- 石綿の世界市場動向2014/2015The report presents a thorough study of asbestos, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing asbestos worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: asbestos production in the country, major manufac …
- 屋内位置情報の世界市場予測（～2022年）：技術、ソフトウェアツール、サービス“Increasing adoption of connected devices is driving the growth of the indoor location market”The global indoor location market size is expected to grow from USD 7.11 billion in 2017 to USD 40.99 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 42.0% during forecast period. The growing trend of digitalization, increasing use of connected devices, and reliable assistance from governments …
- バイオバンクの世界市場2017-2021About biobankingA biobank can be defined as an organized and programed storage of biological materials and corresponding data that can be used in healthcare research. The biological samples vital for medical innovation include tissue, body fluids (such as serum, blood, urine, or fluids from punctures), related derivatives (RNA, DNA, or proteins), and cells. Technavio’s analysts forecast the global …
- 住宅用ガス発電機の世界市場：発電機の種類別（据置型、ポータブル型）、エンドユーザー別（産業、テレコム、住宅、商業）、地域別予測Global Residential Gas Generators Market to reach USD 6.0 billion by 2025. Global Residential Gas Generators Market valued approximately USD 1.8 billion in 2016 is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2017-2025. The increasing number of weather-related power outages and the growing demand for uninterrupted and reliable power supply in developed …
- 小売産業におけるビックデータ：経営者及びITリーダー向けの市場分析Big Data is a reference to a collection of data files/sets so large and complex that it becomes difficult to process using existing database management tools or traditional data processing applications. It has also come to reference the challenges in capturing, organizing, storing, searching, sharing, transferring, analyzing and using this data to improve your business. The trend to Big Data is du …
- 足・足首装具の世界市場About Foot and Ankle DevicesFoot and ankle devices are used for the correction and recuperation of the foot and ankle damaged by injuries or musculoskeletal disorders. The devices can also be used for orthopedic disorders such as osteoarthritis, osteoporosis, bunions, and hammertoes, as well as any congenital or neuropathic condition such as a diabetic foot that requires surgical/non-surgical corr …
- カテーテル安定化装置/カテーテル固定装置の世界市場The global securement devices market is expected to reach $1,372.35 million by 2020 from $957.26 million in 2015, growing at a CAGR of 7.47% between 2015 and 2020. The securement devices product segments included in this report are arterial securement devices, central venous catheter securement devices, peripheral securement devices, abdominal drainage tubes securement devices, epidural securement …
- 世界におけるスマートフォン及びタブレット用タッチパネル動向The popularization of smartphones and tablets has made them the two largest touch panel applications and the touch panel sector one of the few bright spots in the display panel industry. Of all types, projected capacitive touch panels are most commonly used in smartphones and tablets. The bullish market demand for capacitive touch panels is where the competition has come in. This report profiles t …
- 前臨床用画像システムの世界市場：マイクロMRI、マイクロPET、マイクロCT、PAT、SPECT、マルチモダリティー、光学イメージング、超音波装置About Pre-clinical Imaging Pre-clinical Imaging is in vivo imaging of small animals, which had been progressively deployed in drug development process. It helps in the visualizing and monitoring of animals for research with respect to tissue, organ, cell (at molecular level), and physiological and environmental changes. One of the main application areas of pre-clinical imaging is early detection o …
- LatviaのSlaked Lime市場：貿易（輸入、輸出）動向This market research report examines the foreign trade of Latvia and its perspectives on the global market for slaked lime. The report will be of considerable interest primarily to relevant strategic planners, senior company officials and importers/exporters, since it features invaluable information on slaked lime export/import operations in Latvia. The 2002-2012 period is covered, with more empha …
- Leishmaniasis (Kala-Azar)：グローバル臨床試験レビューH1, 2013Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013" provides data on the Leishmaniasis (Kala-Azar) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Leishmaniasis (Kala-Azar). It includes an overview of the trial …
